Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Alzheimer's Disease
  Obstructive Sleep Apnea
• Age: Between 60 Year(s) - 75 Year(s)
• Gender: Male or Female

• Other Inclusion Criteria:
  

  Control (non-OSA) subjects

  1. Participants will not be incapacitated upon enrollment and will not lose capacity throughout their participation in the study
  2. Apnea Hypopnea Index (AHI4%)<15
  3. Male and female subjects with normal cognition and ages 60 to 75
  4. Within normal limits on neurological and psychiatric examinations.
  5. Self-identified as either non-Hispanic white or Black/African-American
  6. Subjects who have a Global Deterioration Scale of 3
  7. Must have agreed to allow their data to be used for future research and to be contacted for future research
  8. Participating in NYULH STUDY ID#: s18-01302 or NYULH STUDY ID#: s20-00427 with available OR will have full clinical evaluation data, neuroimaging measures of vascular burden, amyloid, and nocturnal polysomnography (NPSG) recordings
  9. These studies are ongoing and some of this data will be collected prospectively in this study

  Tau-PET subjects

  1. Subjects enrolled in this study will not be incapacitated upon enrollment and will not lose capacity throughout their participation in the study
  2. Male and female subjects with normal cognition
  3. Within normal limits on neurological and psychiatric examinations.
  4. Self-identified as African-American Black
  5. Subjects who have a Global Deterioration Scale of 3
  6. Must have agreed to allow their data to be used for future research and to be contacted for future research
  7. Participating in NYULH STUDY ID#: s18-01302 with available OR will have full clinical evaluation data, neuroimaging measures of vascular burden, amyloid, and nocturnal polysomnography (NPSG) recordings
  8. This study is ongoing and some of this data will be collected prospectively in this study

  OSA subjects

  1. Subjects enrolled in this study will not be incapacitated upon enrollment and will not lose capacity throughout their participation in the study
  2. Male and female subjects with normal cognition
  3. Within normal limits on neurological and psychiatric examinations.
  4. Self-identified as non-Hispanic white or Black/African-American
  5. Subjects who have a Global Deterioration Scale of 3
  6. Must have agreed to allow their data to be used for future research and to be contacted for future research
  7. Participating in NYULH STUDY ID#: s17-01005, with available OR will have full clinical evaluation data, neuroimaging measures of vascular burden, amyloid, and tau-PET
  8. This study is ongoing and some of this data will be collected prospectively in this study

  
  

You may not be eligible for this study if the following are true:

• 1. Irregular sleep-wake rhythms (based on participant self-report), short sleepers (< 5 hours a day) and long sleepers (> 10 hours a day)
  2. Self-identified as US-born Caribbean Black, Caribbean-born Black or African-born Black
  3. History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders)
  4. Had prior bariatric surgery within 2 years or are currently participating in a medical weight loss program
  5. History of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression)
  6. Geriatric Depression Scale (short form)>6
  7. Insulin dependent diabetes
  8. Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions based off of the PI's discretion
  9. Physical impairment of such severity as to adversely affect the validity of psychological testing
  10. Any prosthetic devices
  11. Medications affecting cognition:
      • Narcotic analgesics
      • Chronic use of medications with anticholinergic activity
      • Anti-Parkinsonian medications
      • Others: amphetamines, amphetamine-like compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine, disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants, cholinesterase inhibitors and memantine
  12. History of a first-degree family member with early onset (age <60 years) dementia
  13. Irregular sleep-wake rhythms based on participant self-report, short sleepers
  14. Presence of any known or suspected obstructive disease of the gastrointestinal tract, including but not limited to diverticulitis and inflammatory bowel disease
  15. History of disorders or impairment of the gag reflex.
  16. Previous gastrointestinal surgery
  17. Previous felinization of the esophagus
  18. Subjects who might undergo Nuclear Magnetic Resonance (NMR) or MRI scanning during the period that the CorTemp® Disposable Temperature Sensor is within the body
  19. Subjects hypomotility disorders of the gastrointestinal tract including but not limited to Ileus
  20. Diagnosis of diverticulosis/diverticulitis
  21. Pregnancy as confirmed by urine pregnancy test prior to the study scan